MBOT

SEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 4

Shoham Moshe · CIK 0001690161 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,592,090

F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions.

SEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 3

Shoham Moshe · CIK 0001690161 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,592,090

F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions.

SEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 2

Shoham Moshe · CIK 0001690161 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,592,090

F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions.

SEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 1

Shoham Moshe · CIK 0001690161 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,592,090

F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions.

SEC source: 0001493152-17-010718 · form4.xml · derivative · entry 2

Gadot Harel · CIK 0001690103 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 476,190

Underlying: Common Stock, par value $0.01 per share · 476,190 shares

Expires 2027-09-14

F2 · derivative.exercise_date: The options vest equally on an annual basis over 60 months commencing on the one year anniversary of the date of grant, and in accordance with the terms of the Issuer's Equity Incentive Plan.

SEC source: 0001493152-17-010718 · form4.xml · derivative · entry 1

Gadot Harel · CIK 0001690103 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,336,522

Underlying: Common Stock, par value $0.01 per share · 1,336,522 shares

Expires 2027-09-14

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

SEC source: 0001493152-17-010597 · form4.xml · nonDerivative · entry 1

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,204,799

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010332 · form-4.xml · nonDerivative · entry 3

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,224,799

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010332 · form-4.xml · nonDerivative · entry 2

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,244,799

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010332 · form-4.xml · nonDerivative · entry 1

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,245,409

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010331 · form4.xml · nonDerivative · entry 2

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,270,409

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010331 · form4.xml · nonDerivative · entry 1

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,275,409

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010330 · form4.xml · nonDerivative · entry 2

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,280,409

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001493152-17-010330 · form4.xml · nonDerivative · entry 1

Bornstein Yoseph · CIK 0001690100 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSA- LifeScience Accelerator Ltd.

Disclosed balance after: 5,295,409

F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities.

SEC source: 0001213900-17-006660 · f4061617lewkowicz_microbot.xml · nonDerivative · entry 1

Lewkowicz Leon · CIK 0001690590 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,078,214

SEC source: 0001213900-16-019069 · f4112816alpha_microbotmed.xml · derivative · entry 3

ALPHA CAPITAL ANSTALT · CIK 0001140358 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,776,457

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

F2 · deemedExecutionDate: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F2 · shares: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · shares: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.

F2 · price: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F2 · derivative.exercise_date: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F2 · derivative.expiration_date: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F2 · derivative.underlying_shares: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · derivative.underlying_shares: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.

F2 · balance_after: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · balance_after: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.

SEC source: 0001213900-16-019069 · f4112816alpha_microbotmed.xml · nonDerivative · entry 2

ALPHA CAPITAL ANSTALT · CIK 0001140358 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,776,457

F1 · deemedExecutionDate: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F1 · shares: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F2 · shares: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · shares: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.

F1 · price: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F1 · balance_after: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F2 · balance_after: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · balance_after: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.

SEC source: 0001213900-16-019069 · f4112816alpha_microbotmed.xml · nonDerivative · entry 1

ALPHA CAPITAL ANSTALT · CIK 0001140358 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,753,549

F1 · deemedExecutionDate: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F1 · shares: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F2 · shares: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · shares: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.

F1 · price: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F1 · balance_after: Pursuant to a merger agreement effective as of November 28, 2016 reported in a Form 8-K filed by the Issuer on November 29, 2016, Alpha Capital Anstalt ("Alpha") was issued 9,753,549 shares of common stock, which immediately following the merger were surrendered by Alpha to the Issuer pursuant to the terms of a Right to Shares Agreement. The Right to Shares Agreement contains a 4.99% "blocker" provision designed to prevent Alpha from being a beneficial owner of more than 4.99% of the Issuer's Common Stock. Therefore, Alpha is no longer an affiliate of the Issuer.

F2 · balance_after: In connection with the merger on November 28, 2016, Alpha exchanged a non-convertible note for a convertible debenture containing a 4.99% "blocker" provision.

F3 · balance_after: The number of shares owned by Alpha does not include any shares issued to Lane Ventures, Inc., a consultant of the Issuer. Alpha disclaims beneficial ownership of any of the shares issued to Lane Ventures, Inc.